Literature DB >> 28870619

A causal Bayesian network model of disease progression mechanisms in chronic myeloid leukemia.

Daniel Koch1, Robert S Eisinger2, Alexander Gebharter2.   

Abstract

Chronic myeloid leukemia (CML) is a cancer of the hematopoietic system initiated by a single genetic mutation which results in the oncogenic fusion protein Bcr-Abl. Untreated, patients pass through different phases of the disease beginning with the rather asymptomatic chronic phase and ultimately culminating into blast crisis, an acute leukemia resembling phase with a very high mortality. Although many processes underlying the chronic phase are well understood, the exact mechanisms of disease progression to blast crisis are not yet revealed. In this paper we develop a mathematical model of CML based on causal Bayesian networks in order to study possible disease progression mechanisms. Our results indicate that an increase of Bcr-Abl levels alone is not sufficient to explain the phenotype of blast crisis and that secondary changes such as additional mutations are necessary to explain disease progression and the poor therapy response of patients in blast crisis.
Copyright © 2017 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Bayesian networks; Blast crisis; Causal modeling; Chronic myeloid leukemia; Disease progression mechanisms; Feedback loops

Mesh:

Substances:

Year:  2017        PMID: 28870619     DOI: 10.1016/j.jtbi.2017.08.023

Source DB:  PubMed          Journal:  J Theor Biol        ISSN: 0022-5193            Impact factor:   2.691


  2 in total

1.  Exploring influencing factors of chronic obstructive pulmonary disease based on elastic net and Bayesian network.

Authors:  Dichen Quan; Jiahui Ren; Hao Ren; Liqin Linghu; Xuchun Wang; Meichen Li; Yuchao Qiao; Zeping Ren; Lixia Qiu
Journal:  Sci Rep       Date:  2022-05-09       Impact factor: 4.996

2.  Recovery preparedness of global air transport influenced by COVID-19 pandemic: Policy intervention analysis.

Authors:  Chunli Zhu; Jianping Wu; Mingyu Liu; Linyang Wang; Duowei Li; Anastasios Kouvelas
Journal:  Transp Policy (Oxf)       Date:  2021-03-26
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.